Solutions

Online Inquiry

* Your Name

Phone Number

* E-mail Address

* Services Interested

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Medulloepithelioma

Diagnostics and therapeutics for medulloepitheliomas, which are aggressive and extremely rare tumors, have been quite challenging. Protheragen is building the future with innovative diagnostics, therapeutics, and preclinical research services. With our unique capability of comprehensive animal model development and research, we are able to efficiently address medulloepithelioma which makes us a trustworthy ally in the battle with it.

Introduction to Medulloepithelioma

Medulloepithelioma is an extremely uncommon pediatric ocular neoplasm, ranked as the second most frequent primary intraocular tumor after retinoblastoma and mostly diagnosed before age ten. Arising typically from the non‑pigmented ciliary epithelium of the pars plicata, these lesions are designated ciliary body medulloepithelioma — the predominant anatomical variant of this embryonal tumor — while rare cases originate from the retina or optic nerve. Histologically, it resembles developing retinal structures and the embryonic neural tube, featuring pseudostratified neuroepithelium within hyaluronic‑acid‑rich stroma. Sporadic non‑familial cases may be linked to DICER1‑related tumor predisposition syndromes, and clinical presentations include vision loss, ocular pain, leukocoria and secondary glaucoma; it is often misdiagnosed as retinoblastoma or persistent hyperplastic primary vitreous.

Histopathological analysis of ciliary body medulloepithelioma.

Fig.1 Histopathologic image of ciliary body medulloepithelioma by hematoxylin-eosin staining. (He J., et al., 2023)

Medulloepitheliomas can be subdivided into teratoid and non-teratoid types with the latter containing cartilage, neuroglial tissue, or rhabdomyoblasts as heteroplastic elements. Because the tumor grows insidiously and remains quiescent for long periods, it is usually associated with secondary complications like cataracts, glaucoma, and vision loss.

Diagnostic Methods for Medulloepithelioma

Histopathological Examination

Histopathology remains the anchor of medulloepithelioma diagnostics. The tumor consists of undulating neuroepithelial cell cords within hyaluronic-acid-rich stroma. Immunohistochemical markers vimentin, neuron-specific enolase (NSE), and cytokeratin aid diagnosis. For ciliary-body-origin lesions, NSE, vimentin and GFAP confirm neuroepithelial origin; teratoid and non-teratoid classification applies regardless of tumor location.

Fine-Needle Aspiration Biopsy

Fine-needle aspiration biopsy has begun to gain prominence as an important tool in the diagnosis of medulloepithelioma. This procedure can provide tumor cell samples for examination of pertinent features which range from pseudostratified neuroepithelium undifferentiated neuroblasts. FNA reduces the need for more invasive procedures while concomitantly providing a diagnosis in a much shorter period.

Molecular Diagnostics

The diagnosis of medulloepithelioma increasingly relies on tumor genetic sequencing and other molecular diagnostics. Detection of DICER1 mutations is critical for understanding tumor etiology and guiding targeted therapeutic interventions. Furthermore, analysis of other genetic markers and oncogenic pathways may elucidate the molecular basis of tumor initiation and progression, supporting precise diagnosis, risk stratification and personalized-treatment development.

Therapeutics Development for Medulloepithelioma

Current therapeutic strategies for medulloepithelioma focus on surgical resection combined with adjuvant therapies to reduce recurrence and control local or metastatic lesions.

Chemotherapy: Systemic VEC-based regimens are widely used for adjuvant treatment to debulk tumors pre-operatively and manage residual or metastatic disease; intra-arterial delivery achieves higher local drug exposure while lowering systemic toxicities.
Targeted Therapy: Tyrosine kinase inhibitors are under preclinical investigation to block VEGF- and PDGF-driven oncogenic signaling, suppressing tumor proliferation and angiogenesis for refractory cases.
Immunotherapy: Immune checkpoint inhibitors remain investigational for medulloepithelioma, aiming to activate endogenous anti-tumor immunity for improved long-term disease control.

Our Services

Protheragen offers a wide range of services to support medulloepithelioma diagnostics and therapeutics development. These include custom animal model development, high-throughput drug screening, biomarker discovery, and translational research. Our team of experts is dedicated to providing tailored solutions to meet the unique challenges of medulloepithelioma therapy development.

Diagnostics Development

Karyotype Analysis Service
Omics Analysis Service
Biomarker Development Service
Artificial Intelligence Service
Customized Diagnostics Development Service

Therapeutic Development

Disease Models

Human Medulloepithelioma Cell-Derived Tumor Xenograft (CDX) Models
Medulloepithelioma Orthotopic Models
3D Organoid Models

Preclinical Research

Protheragen offers comprehensive in vitro and in vivo animal model development services to support medulloepithelioma research. Our in vitro services include the establishment of primary cell cultures and 3D organoid models, which provide a platform for high-throughput drug screening. If you are interested in our services, please feel free to contact us.

References

He, Jing, et al. "Analysis of clinical and pathological features of ciliary body medulloepithelioma." International Journal of Ophthalmology 16.3 (2023): 382.
Tadepalli, Sameeksha H., et al. "Intraocular medulloepithelioma–A review of clinical features, DICER 1 mutation, and management." Indian journal of ophthalmology 67.6 (2019): 755-762.
Saunders, Timothy, and Curtis E. Margo. "Intraocular medulloepithelioma." Archives of pathology & laboratory medicine 136.2 (2012): 212-216.
Coc, Ivana Romac, et al. "Evaluation of Ciliary Body Medulloepitheliomas in candidates for phakic lens implantation." International Ophthalmology 44.1 (2024): 402.
Schmalfuss, Tiago Ribeiro, Egidio Picetti, and Helena Messinger Pakter. "Glaucoma due to Ciliary Body Medulloepitheliomas and pseudoplateau iris: a systematic review of the literature." Arquivos Brasileiros de Oftalmologia 81 (2018): 254-261.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.